MYC and small cell lung carcinoma: MYC amplification or overexpression is one of the well-known genomic alterations in SCLC, which is observed in approximately 30% of SCLC, and RPM tumors have been previously shown to be highly aggressive and resistant to multiple therapies (Rudin et al., 2012; George et al., 2015; Chalishazar et al., 2019; Ireland et al., 2020; Mollaoglu et al., 2017).